Cancer immunotherapy via nucleic acid aptamers

International Immunopharmacology

Volumn 29, Issue 2, 2015, Pages 926-936

  Khedri, Mostafa ^a   Rafatpanah, Houshang ^a   Abnous, Khalil ^b   Ramezani, Pouria ^b   Ramezani, Mohammad ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aptamer; Cancer; Delivery system; Immunotherapy

Indexed keywords

APTAMER; CD137 LIGAND; CD28 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; NUCLEIC ACID; OX40 LIGAND; IMMUNOLOGICAL ADJUVANT;

ARTICLE; CANCER IMMUNOTHERAPY; DRUG DELIVERY SYSTEM; EX VIVO STUDY; HUMAN; IN VIVO STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; APTAMERS, NUCLEOTIDE; HUMANS; IMMUNOTHERAPY; NEOPLASMS; SELEX APTAMER TECHNIQUE;

EID: 84948465026     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.10.013     Document Type: Review

References (110)

1. M. Dougan, and G. Dranoff Immunotherapy of cancer Innate Immune Regulation and Cancer Immunotherapy 2012 Springer 391 414
2. M.D. Vesely, M.H. Kershaw, R.D. Schreiber, and M.J. Smyth Natural innate and adaptive immunity to cancer Annu. Rev. Immunol. 29 2011 235 271
3. G. Mayer The chemical biology of aptamers Angew. Chem. Int. Ed. 48 2009 2672 2689
4. A.D. Ellington, and J.W. Szostak In vitro selection of RNA molecules that bind specific ligands Nature 346 1990 818 822
5. C. Tuerk, and L. Gold Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 1990 505 510
6. D.L. Robertson, and G.F. Joyce Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA Nature 344 1990 467 468
7. C.M. Dollins, S. Nair, D. Boczkowski, J. Lee, J.M. Layzer, E. Gilboa, and et al. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer Chem. Biol. 15 2008 675 682
8. L.A. Wheeler, V. Vrbanac, R. Trifonova, M.A. Brehm, A. Gilboa-Geffen, S. Tanno, and et al. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras Mol. Ther. 21 2013 1378 1389
9. S. Santulli-Marotto, S.K. Nair, C. Rusconi, B. Sullenger, and E. Gilboa Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity Cancer Res. 63 2003 7483 7489
10. J. Weber Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events Oncologist 12 2007 864 872
11. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 2010 711 723
12. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.-J. Hwu, R. Kefford, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2013 134 144
13. T. Mairal, V.C. Özalp, P.L. Sánchez, M. Mir, I. Katakis, and C.K. O'Sullivan Aptamers: molecular tools for analytical applications Anal. Bioanal. Chem. 390 2008 989 1007
14. M. Caporale, P. Centorame, A. Giovannini, F. Sacchini, M. Di Ventura, M. De las Heras, and et al. Infection of lung epithelial cells and induction of pulmonary adenocarcinoma is not the most common outcome of naturally occurring JSRV infection during the commercial lifespan of sheep Virology 338 2005 144 153
15. B.C. Wengerter, J.A. Katakowski, J.M. Rosenberg, C.G. Park, S.C. Almo, D. Palliser, and et al. Aptamer-targeted Antigen Delivery Mol. Ther. 2014
16. S.K.N. Sandra Santulli-Marotto, C. Rusconi, B. Sullenger, and E. Gilboa Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity Cancer Res. 1 2003 7483 7489
17. H. Sun, X. Zhu, P.Y. Lu, R.R. Rosato, W. Tan, and Y. Zu Oligonucleotide aptamers: new tools for targeted cancer therapy Mol. Ther.-Nucleic Acids 3 2014 e182
18. J.P. Overington, B. Al-Lazikani, and A.L. Hopkins How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996
19. S. Gnjatic, H. Nishikawa, A.A. Jungbluth, A.O. Güre, G. Ritter, E. Jäger, and et al. NY-ESO-1: review of an immunogenic tumor antigen Adv. Cancer Res. 95 2006 1 30
20. Meyer C, Hahn U, Rentmeister A. Cell-specific aptamers as emerging therapeutics. J. Nucleic Acids 2011;2011.
21. S. Ohuchi Cell-SELEX technology BioResearch open access. 1 2012 265 272
22. J.O. McNamara, E.R. Andrechek, Y. Wang, K.D. Viles, R.E. Rempel, E. Gilboa, and et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras Nat. Biotechnol. 24 2006 1005 1015
23. C.M. Dollins, S. Nair, and B.A. Sullenger Aptamers in immunotherapy Hum. Gene Ther. 19 2008 443 450
24. P. Sharma Immune Checkpoint Strategies Introduction Proceedings of the 2012 ASCO Annual Meeting, Clinical Science Symposium 2012 1 5
25. A. Ozer, J.M. Pagano, and J.T. Lis New technologies provide quantum changes in the scale, speed, and success of SELEX methods and aptamer characterization Mol. Ther.-Nucleic Acids 3 2014 e183
26. R. Stoltenburg, C. Reinemann, and B. Strehlitz SELEX - a (r) evolutionary method to generate high-affinity nucleic acid ligands Biomol. Eng. 24 2007 381 403
27. S.M. Shamah, J.M. Healy, and S.T. Cload Complex target SELEX Acc. Chem. Res. 41 2008 130 138
28. K. Sefah, D. Shangguan, X. Xiong, M.B. O'Donoghue, and W. Tan Development of DNA aptamers using cell-SELEX Nat. Protoc. 5 2010 1169 1185
29. A. Berezhnoy, C.A. Stewart, J.O. Mcnamara II, W. Thiel, P. Giangrande, G. Trinchieri, and et al. Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing Mol. Ther. 2012
30. P. Parekh, S. Kamble, N. Zhao, Z. Zeng, B.P. Portier, and Y. Zu Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer Biomaterials 34 2013 8909 8917
31. K. Palucka, and J. Banchereau Cancer immunotherapy via dendritic cells Nat. Rev. Cancer 12 2012 265 277
32. P.J. Tacken, I.J.M. de Vries, R. Torensma, and C.G. Figdor Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting Nat. Rev. Immunol. 7 2007 790 802
33. J.-C.D. Schwartz, X. Zhang, S.G. Nathenson, and S.C. Almo Structural mechanisms of costimulation Nat. Immunol. 3 2002 427 434
34. A. Molckovsky, and L.L. Siu First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology J. Hematol. Oncol. 1 2008 20
35. E.J. Small, N.S. Tchekmedyian, B.I. Rini, L. Fong, I. Lowy, and J.P. Allison A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin. Cancer Res. 13 2007 1810 1815
36. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N. Engl. J. Med. 364 2011 2517 2526
37. J.O. McNamara, D. Kolonias, F. Pastor, R.S. Mittler, L. Chen, P.H. Giangrande, and et al. Multivalent 4-1BB binding aptamers costimulate CD8 + T cells and inhibit tumor growth in mice J. Clin. Invest. 118 2008 376 386
38. H.-W. Lee, S.-J. Park, B.K. Choi, H.H. Kim, K.-O. Nam, and B.S. Kwon 4-1BB promotes the survival of CD8 + T lymphocytes by increasing expression of Bcl-xL and Bfl-1 J. Immunol. 169 2002 4882 4888
39. I. Melero, W.W. Shuford, S.A. Newby, A. Aruffo, J.A. Ledbetter, K.E. Hellström, and et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors Nat. Med. 3 1997 682 685
40. K.F. May, L. Chen, P. Zheng, and Y. Liu Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8 + T cells Cancer Res. 62 2002 3459 3465
41. M. Sznol, F. Hodi, K. Margolin, D. McDermott, M. Ernstoff, J. Kirkwood, and et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) J. Clin. Oncol. 2008 3007 (Meeting Abstracts)
42. P.A. Ascierto, E. Simeone, M. Sznol, Y.-X. Fu, and I. Melero Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies Seminars in Oncology 2010 Elsevier 508 516
43. N.P. Restifo, M.E. Dudley, and S.A. Rosenberg Adoptive immunotherapy for cancer: harnessing the T cell response Nat. Rev. Immunol. 12 2012 269 281
44. M. Croft, T. So, W. Duan, and P. Soroosh The significance of OX40 and OX40L to T-cell biology and immune disease Immunol. Rev. 229 2009 173 191
45. K. Garber Beyond ipilimumab: new approaches target the immunological synapse J. Natl. Cancer Inst. 103 2011 1079 1082
46. M. Kovacsovics-Bankowski, L. Chisholm, J. Vercellini, M. Crittenden, S. Lary, B. Curti, and et al. Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis J. Immunother. Cancer 1 2013 1-
47. Talmage DW, Woolnough JA, Hemmingsen H, Lopez L, Lafferty KJ. Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor (s). Proc. Natl. Acad. Sci. 1977;74:4610-4.
48. E.D. Pratico, B.A. Sullenger, and S.K. Nair Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40 Nucleic Acid Ther. 23 2013 35 43
49. G. Driessens, J. Kline, and T.F. Gajewski Costimulatory and coinhibitory receptors in anti-tumor immunity Immunol. Rev. 229 2009 126 144
50. A.K. Salama, and F.S. Hodi Cytotoxic T-lymphocyte-associated antigen-4 Clin. Cancer Res. 17 2011 4622 4628
51. J. Song, F.T. Lei, X. Xiong, and R. Haque Intracellular signals of T cell costimulation Cell. Mol. Immunol. 5 2008 239 247
52. G. Suntharalingam, M.R. Perry, S. Ward, S.J. Brett, A. Castello-Cortes, M.D. Brunner, and et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 N. Engl. J. Med. 355 2006 1018 1028
53. F. Pastor, M.M. Soldevilla, H. Villanueva, D. Kolonias, S. Inoges, A.L. de Cerio, and et al. CD28 aptamers as powerful immune response modulators Mol. Ther.-Nucleic Acids 2 2013 e98
54. J.M. Chemnitz, R.V. Parry, K.E. Nichols, C.H. June, and J.L. Riley SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation J. Immunol. 173 2004 945 954
55. T. Okazaki, S. Chikuma, Y. Iwai, S. Fagarasan, and T. Honjo A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat. Immunol. 14 2013 1212 1218
56. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J. 11 1992 3887
57. C. Robert, A. Ribas, J.D. Wolchok, F.S. Hodi, O. Hamid, R. Kefford, and et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 384 2014 1109 1117
58. N.A. Rizvi, J. Mazières, D. Planchard, T.E. Stinchcombe, G.K. Dy, S.J. Antonia, and et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Lancet Oncol. 16 2015 257 265
59. A. Prodeus, A. Abdul-Wahid, N.W. Fischer, E.H. Huang, M. Cydzik, and J. Gariépy Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers Mol. Ther.-Nucleic Acids 4 2015 e237
60. M.-L. Chen, M.J. Pittet, L. Gorelik, R.A. Flavell, R. Weissleder, H. von Boehmer, and et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo Proc. Natl. Acad. Sci. U. S. A. 102 2005 419 424
61. L. Gorelik, and R.A. Flavell Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells Nat. Med. 7 2001 1118 1122
62. Q. Zhang, X. Yang, M. Pins, B. Javonovic, T. Kuzel, S.-J. Kim, and et al. Adoptive transfer of tumor-reactive transforming growth factor-β-insensitive CD8 + T cells: eradication of autologous mouse prostate cancer Cancer Res. 65 2005 1761 1769
63. N. Seo, S. Hayakawa, M. Takigawa, and Y. Tokura Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4 + T-regulatory cells and systemic collapse of antitumour immunity Immunology 103 2001 449 457
64. C.A. Ogden, J.D. Pound, B.K. Batth, S. Owens, I. Johannessen, K. Wood, and et al. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma J. Immunol. 174 2005 3015 3023
65. P. Khaw, F. Grehn, G. Hollo, B. Overton, R. Wilson, R. Vogel, and et al. A phase III study of subconjunctival human anti-transforming growth factor beta (2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy Ophthalmology 114 2007 1822 1830
66. C.P. Denton, P.A. Merkel, D.E. Furst, D. Khanna, P. Emery, V.M. Hsu, and et al. Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192 Arthritis Rheum. 56 2007 323 333
67. L. Llorente, Y. Richaud-Patin, C. García-Padilla, E. Claret, J. Jakez-Ocampo, M.H. Cardiel, and et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus Arthritis Rheum. 43 2000 1790 1800
68. X. Zhu, L. Li, L. Zou, X. Zhu, G. Xian, H. Li, and et al. A novel aptamer targeting TGF-β receptor II inhibits transdifferentiation of human tenon's fibroblasts into myofibroblast Invest. Ophthalmol. Vis. Sci. 53 2012 6897 6903
69. T.G. McCauley, J.C. Kurz, P.G. Merlino, S.D. Lewis, M. Gilbert, D.M. Epstein, and et al. Pharmacologic and pharmacokinetic assessment of anti-TGFβ2 aptamers in rabbit plasma and aqueous humor Pharm. Res. 23 2006 303 311
70. D.H. Bunka, O. Platonova, and P.G. Stockley Development of aptamer therapeutics Curr. Opin. Pharmacol. 10 2010 557 562
71. M.L. Harrison, E. Obermueller, N.R. Maisey, S. Hoare, K. Edmonds, N.F. Li, and et al. Tumor necrosis factor α as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose J. Clin. Oncol. 25 2007 4542 4549
72. N.-R. Han, H.-M. Kim, and H.-J. Jeong The β-sitosterol attenuates atopic dermatitis-like skin lesions through down-regulation of TSLP Exp. Biol. Med. 239 2014 454 464
73. M. Boita, M. Garzaro, L. Raimondo, G. Riva, J. Mazibrada, G. Pecorari, and et al. Eosinophilic inflammation of chronic rhinosinusitis with nasal polyps is related to OX40 ligand expression Innate Immun. 2014 (1753425914523460)
74. C. Milstein, and A. Cuello Hybrid Hybridomas and Their use in Immunohistochemistry 1983
75. S. Stamova, S. Koristka, J. Keil, C. Arndt, A. Feldmann, I. Michalk, and et al. Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs Antibodies. 1 2012 172 198
76. R.E. Kontermann Recombinant bispecific antibodies for cancer therapy Acta Pharmacol. Sin. 26 2005 1 9
77. A. Boltz, B. Piater, L. Toleikis, R. Guenther, H. Kolmar, and B. Hock Bi-specific aptamers mediating tumor cell lysis J. Biol. Chem. 286 2011 21896 21905
78. M. Vitale, C. Cantoni, G. Pietra, M.C. Mingari, and L. Moretta Effect of tumor cells and tumor microenvironment on NK-cell function Eur. J. Immunol. 2014
79. J.P. Eder, G.F.V. Woude, S.A. Boerner, and P.M. LoRusso Novel therapeutic inhibitors of the c-Met signaling pathway in cancer Clin. Cancer Res. 15 2009 2207 2214
80. A. Berezhnoy, I. Castro, A. Levay, T.R. Malek, and E. Gilboa Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity J. Clin. Investig. 124 2014 188
81. G.B. Klintmalm, S. Saab, J.C. Hong, and B. Nashan The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy Clin. Transpl. 2014
82. K.-M. Song, S. Lee, and C. Ban Aptamers and their biological applications Sensors 12 2012 612 631
83. S. Nair Prostate cancer immunotherapy by targeting dendritic cells in vivo using receptor-specific aptamer conjugated to prostate stem cell antigen (PSCA)-encoding RNA DTIC Document 2011
84. A. Mukherjee, T. Darlington, R. Baldwin, C. Holz, S. Olson, P. Kulkarni, and et al. Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen ChemMedChem 2014
85. S.E. Lupold, B.J. Hicke, Y. Lin, and D.S. Coffey Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen Cancer Res. 62 2002 4029 4033
86. J.P. Dassie, L. X-y, G.S. Thomas, R.M. Whitaker, K.W. Thiel, K.R. Stockdale, and et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors Nat. Biotechnol. 27 2009 839 846
87. T.C. Chu, J.W. Marks, L.A. Lavery, S. Faulkner, M.G. Rosenblum, A.D. Ellington, and et al. Aptamer: toxin conjugates that specifically target prostate tumor cells Cancer Res. 66 2006 5989 5992
88. M.C. Shin, J. Zhao, J. Zhang, Y. Huang, H. He, M. Wang, and et al. Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction J. Biomed. Mater. Res. Part A 2014
89. T.S. Johnson, K. Mahnke, V. Storn, K. Schönfeld, S. Ring, D.M. Nettelbeck, and et al. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule Clin. Cancer Res. 14 2008 8169 8177
90. S.A. Rosenberg Shedding light on immunotherapy for cancer N. Engl. J. Med. 350 2004 1461
91. A. Haberland, G. Wallukat, S. Berg, A.-M. Schulz, E.-J. Freyse, R. Vetter, and et al. Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats Mol. Cell. Biochem. 2014 1 4
92. L. Beigelman, J.A. McSwiggen, K.G. Draper, C. Gonzalez, K. Jensen, A.M. Karpeisky, and et al. Chemical modification of hammerhead ribozymes catalytic activity and nuclease resistance J. Biol. Chem. 270 1995 25702 25708
93. W.A. Pieken, D.B. Olsen, F. Benseler, H. Aurup, and F. Eckstein Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes Science 253 1991 314 317
94. C.E. Tucker, L.-S. Chen, M.B. Judkins, J.A. Farmer, S.C. Gill, and D.W. Drolet Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys J. Chromatogr. B Biomed. Sci. Appl. 732 1999 203 212
95. M.C. Willis, B. Collins, T. Zhang, L.S. Green, D.P. Sebesta, C. Bell, and et al. Liposome-anchored vascular endothelial growth factor aptamers § Bioconjug. Chem. 9 1998 573 582
96. A.Z. Wang, V. Bagalkot, C.C. Vasilliou, F. Gu, F. Alexis, L. Zhang, and et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy ChemMedChem 3 2008 1311 1315
97. D. Kim, Y.Y. Jeong, and S. Jon A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer ACS Nano 4 2010 3689 3696
98. O.C. Farokhzad, J. Cheng, B.A. Teply, I. Sherifi, S. Jon, P.W. Kantoff, and et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc. Natl. Acad. Sci. 103 2006 6315 6320
99. M.F. Bachmann, and G.T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10 2010 787 796
100. E. Kraus, W. James, and A.N. Barclay Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4 + T lymphocyte function J. Immunol. 160 1998 5209 5212
101. F. Chauveau, Y. Aissouni, J. Hamm, H. Boutin, D. Libri, F. Ducongé, and et al. Binding of an aptamer to the N-terminal fragment of VCAM-1 Bioorg. Med. Chem. Lett. 17 2007 6119 6122
102. R.D. Jenison, S.D. Jennings, D.W. Walker, R.F. Bargatze, and D. Parma Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion Antisense Nucleic Acid Drug Dev. 8 1998 265 279
103. B.J. Hicke, S.R. Watson, A. Koenig, C.K. Lynott, R.F. Bargatze, Y.-F. Chang, and et al. DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice J. Clin. Investig. 98 1996 2688
104. S. Jeong, T.-Y. Eom, S.-J. Kim, S.-W. Lee, and J. Yu In vitro selection of the RNA aptamer against the sialyl Lewis X and its inhibition of the cell adhesion Biochem. Biophys. Res. Commun. 281 2001 237 243
105. Y. Liu, N. Tuleouva, E. Ramanculov, and A. Revzin Aptamer-based electrochemical biosensor for interferon gamma detection Anal. Chem. 82 2010 8131 8136
106. J. Kang, M.S. Lee, J.A. Copland III, B.A. Luxon, and D.G. Gorenstein Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-β1 protein Bioorg. Med. Chem. Lett. 18 2008 1835 1839
107. R.M. Boomer, S.D. Lewis, J.M. Healy, M. Kurz, C. Wilson, and T.G. McCauley Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues Oligonucleotides 15 2005 183 195
108. M.L. Marro, D.A. Daniels, A. McNamee, D.P. Andrew, T.D. Chapman, M.S. Jiang, and et al. Identification of potent and selective RNA antagonists of the IFN-γ-inducible CXCL10 chemokine Biochemistry 44 2005 8449 8460
109. A. Rhodes, N. Smithers, T. Chapman, S. Parsons, and S. Rees The generation and characterisation of antagonist RNA aptamers to MCP-1 FEBS Lett. 506 2001 85 90
110. A. Rhodes, A. Deakin, J. Spaull, B. Coomber, A. Aitken, P. Life, and et al. The generation and characterization of antagonist RNA aptamers to human oncostatin M J. Biol. Chem. 275 2000 28555 28561